Safety and immunogenicity of homologous versus heterologous booster dose with AZD1222, mRNA-1273, or MVC-COV1901 SARS-CoV-2 vaccines in adults: An observer-blinded, multi-center, phase 2 randomized trial.

"appendix a supplementary material the following are the supplementary data to this article: supplementary data 1 supplementary data 2 data availability data will be made available on request."

"Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: L.E., P.F.T., Y.J.W., H.Y.C., J.A.E, C.C., and C.E.L. are employees of Medigen Vaccine Biologics Corporation. A.W. received consultancy fee from Medigen Vaccine Biologics Corporation. Other authors report no conflict of interest."

"Funding source Medigen Vaccine Biologics Corporation (MVC) and Coalition for Epidemic Preparedness Innovations (CEPI) co-funded the trial and had a role in trial design."

"ClinicalTrials.gov registration NCT05197153"